Septic Shock Clinical Trial
Official title:
Randomized Controlled Clinical Trial of Antioxidant Therapy in Critically Ill Patients With Septic Shock: Analysis Before and After Treatment of the Oxidative Stress
Verified date | August 2021 |
Source | American British Cowdray Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sepsis and septic shock are public health problems worldwide that represents an excessive cost for health systems. Despite the great technological and research advances, mortality can reach up to 80% in patients with multiple organ failure (FOM). Therapeutic studies focused on evaluating the usefulness of the use of antioxidants have shown different outcomes and results. This randomized clinical trial in patients with septic shock at two general intensive care units try to evaluate the usefulness of four different antioxidant therapies added to the conventional treatment, which includes: n-acetyl cysteine, vitamin C, vitamin E and melatonin. Measurement of parameters before and after treatment of oxidative stress includes nitrates and nitrites, lipid peroxidation, glutathione peroxidase, glutathione s transferase, extracellular activity of SOD, GSH concentration and evaluation of total antioxidant capacity. The investigators will also evaluate the clinical impact of antioxidant therapy with the SOFA score.
Status | Active, not recruiting |
Enrollment | 131 |
Est. completion date | June 2022 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of septic shock in the last 24 hours characterized by refractory hypotension and vasopressor requirement despite sufficient fluid resuscitation (20 mL/kg of colloids or 40 mL/kg of crystalloids) to maintain a blood pressure = 65 mmHg with a lactate> 2 mmol/L. - Admitted to the ICU of the ABC Medical Center. - Give informed consent. Exclusion Criteria: - Patients who refuse to be included. - Chronic or recent use of steroids. - Use of statins. - Patients receiving some type of antioxidant treatment. - Any contraindication to the use of vitamin C, vitamin E, n-acetylcysteine or melatonin. - Pregnant women. |
Country | Name | City | State |
---|---|---|---|
Mexico | Centro Médico ABC | Mexico City |
Lead Sponsor | Collaborator |
---|---|
American British Cowdray Medical Center |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | TNF-a | Inflammatory Response Pathway | Immediately before treatment and 48 hours after therapy | |
Other | IL-1 | Inflammatory Response Pathway | Immediately before treatment and 48 hours after therapy | |
Other | IL-6 | Inflammatory Response Pathway | Immediately before treatment and 48 hours after therapy | |
Other | Ionized Ca2+ | Electrolytes | Immediately before treatment and 48 hours after therapy | |
Other | Ionized Mg2+ | Electrolytes | Immediately before treatment and 48 hours after therapy | |
Primary | Organic failure measurement by the Sequential Organ Failure Assessment Score (SOFA) | The SOFA score is used to track a person's status during the stay in an intensive care unit (ICU) to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The worst physiological variables is collected serially every 24 hours of a patient's ICU admission. The "worst" measurement is defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24. The investigators are going to evaluate the daily total score and the trend before and after the administration of the therapy. | Up to 7 days (1 week). From date of randomization and every 24 hours until discharge from the intensive care unit or date of death from any cause, whichever came first, assessed up to 7 days. | |
Secondary | Nitrates and nitrites levels | Oxidative stress | Immediately before treatment and 48 hours after therapy | |
Secondary | Malondialdehyde levels | Lipid peroxidation | Immediately before treatment and 48 hours after therapy | |
Secondary | Total antioxidant capacity | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Glutathione Peroxidase Enzyme Activity | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Glutathione S-transferase Activity | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Extracellular Superoxide Dismutase Activity | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Glutathione concentration | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Selenium | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Vitamin C | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Thioredoxin | Antioxidant status | Immediately before treatment and 48 hours after therapy | |
Secondary | Carbonylation | Pro-oxidant status | Immediately before treatment and 48 hours after therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 |